Basics Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. IPO Date: March 24, 2018 Sector: Healthcare Industry: Biotech Market Cap: $1.02B Activated in VL: True Average Daily Range Avg Daily Range: $0.13 | 3.55% Avg Daily Range (30 D): $0.08 | 2.06% Avg Daily Range (90 D): $0.09 | 3.57% Institutional Daily Volume Avg Daily Volume: 2.67M Avg Daily Volume (30 D): 3.73M Avg Daily Volume (90 D): 4.67M Trade Size Avg Trade Size (Sh.): 308 Avg Trade Size (Sh.) (30 D): 251 Avg Trade Size (Sh.) (90 D): 321 Institutional Trades Total Inst.Trades: 883 Avg Inst. Trade: $1.65M Avg Inst. Trade (30 D): $1.78M Avg Inst. Trade (90 D): $1.46M Avg Inst. Trade Volume: .47M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.58M Avg Closing Trade (30 D): $1.93M Avg Closing Trade (90 D): $1.5M Avg Closing Volume: 468.01K     News Jul 8, 2025 @ 12:00 PM Akebia Therapeutics to Present at the H.C. Wainwri... Source: Mercedes Carrasco Jun 16, 2025 @ 10:00 AM AVEROA receives European marketing authorization f... Source: N/A May 28, 2025 @ 12:00 PM Akebia Therapeutics to Present at the Jefferies Gl... Source: N/A Apr 2, 2025 @ 9:00 AM AVEROA Receives Positive Opinion from the European... Source: N/A Mar 20, 2025 @ 2:17 AM Akebia Therapeutics Announces Pricing of Public Of... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-.22 $.03 $-.11 Diluted EPS $-.22 $.03 $-.11 Revenue $ 184.91M $ 57.34M $ 46.5M Gross Profit $ 125.71M $ 49.71M $ 26.13M Net Income / Loss $ -45.31M $ 6.11M $ -22.8M Operating Income / Loss $ -22.02M $ 13.51M $ -14.31M Cost of Revenue $ 59.2M $ 7.63M $ 20.37M Net Cash Flow $ 70.48M $ 61.51M $ 17.86M PE Ratio